Barbara Burtness, MD

Panelists discuss the standard management of recurrent/metastatic nasopharyngeal carcinoma (NPC), emphasizing surgery or re-irradiation when feasible, and gemcitabine-cisplatin chemotherapy as the systemic backbone, while highlighting the need for more effective therapies to improve long-term outcomes.

Panelists discuss the distinct Epstein-Barr virus (EBV)-driven biology of nasopharyngeal carcinoma (NPC), the role of plasma EBV DNA as a biomarker, and the strong evidence supporting gemcitabine-based induction chemotherapy followed by chemoradiotherapy as standard treatment for locally advanced disease.

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

Shravan Kandula, MD, presents the case of a patient with locally recurrent nasopharyngeal carcinoma.

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.

Barbara Burtness, MD, discusses findings from a subgroup analysis from the phase 2 E3311 trial in HPV-associated oropharynx cancer.

Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma and lung cancer.

Barbara Burtness, MD, discusses the efficacy of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.

Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the future of immunotherapy in head and neck cancer.

Barbara Burtness, MD, professor of Medicine (Medical Oncology) Disease Aligned Research Team Leader, Head and Neck Cancers Program co-director, Developmental Therapeutics Research Program of Yale Cancer Center, discusses the use of biomarkers in metastatic head and neck squamous cell carcinoma.

Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the promise of frontline pembrolizumab in the treatment of patients with metastatic head and neck squamous cell carcinoma.

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses the benefit of pembrolizumab (Keytruda) as a treatment for patients with recurrent metastatic head and neck squamous cell carcinoma.

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses frontline immunotherapy in head and neck cancer.

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses findings from the KEYNOTE-048 in head and neck squamous cell carcinoma (HNSCC).

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the evolution of molecular testing in head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the use of immunotherapy in patients with head and neck cancer who have residual disease following treatment with chemotherapy and radiation.